Cargando…
Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
PURPOSE: Although five-alpha reductase inhibitor (5-ARI) is one of standard treatment for benign prostatic hyperplasia (BPH) or alopecia, potential complications after 5-ARI have been issues recently. This study aimed to investigate the risk of depression after taking 5-ARI and to quantify the risk...
Autores principales: | Kim, Jae Heon, Shim, Sung Ryul, Khandwala, Yash, Del Giudice, Francesco, Sorensen, Simon, Chung, Benjamin I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Sexual Medicine and Andrology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502319/ https://www.ncbi.nlm.nih.gov/pubmed/31190484 http://dx.doi.org/10.5534/wjmh.190046 |
Ejemplares similares
-
Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018) -
Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014) -
5-alpha reductase inhibitors use in prostatic disease and beyond
por: Chislett, Bodie, et al.
Publicado: (2023) -
5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023) -
Prevalence of Postprostatectomy Incontinence Requiring Anti-incontinence Surgery After Radical Prostatectomy for Prostate Cancer: A Retrospective Population-Based Analysis
por: Kim, Jae Heon, et al.
Publicado: (2021)